Search Results - stephen+baylin

11 Results

Sort By:

Using DNA Methylation Markers To Create a Molecular Staging Paradigm for Solid Malignancies and To Predict Cancer Recurrence and Patient Survival

Technology: Currently, cancer recurrence in solid malignancies occurs in many patients after complete curative surgery despite no additional histological evidence of remaining cancer outside the area of resection, especially in the surrounding lymph nodes. It is believed that in patients with recurrent disease, micrometastases reside that are undetectable...

Published: 6/27/2024 | Inventor(s): James Herman, Stephen Baylin, Malcolm Brock

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, Epigenetic, In Vitro Diagnostics, Methylation, Risk Stratification

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Computers, Electronics & Software > Precision Medicine Tools, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Computers, Electronics & Software, Technology Classifications > Diagnostics

Compositions and Methods for Treating Solid Tumors

UNMET NEEDCancers are now recognized as being driven by widespread changes in the epigenome including changes in DNA methylation and chromatin packaging. Changes in DNA methylation include global loss of methylation and focal gain of methylation at promoter regions of tumor suppressor genes leading to transcriptional silencing. DNA methylation, the...

Published: 6/27/2024 | Inventor(s): Cynthia Zahnow, Stephen Baylin, Michael Topper, Meredith Stone

Keywords(s): Cancers, Chemotherapy/Chemotherapy, Combination, Disease Indication, Therapeutic Matter, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers

Improved Treatment Prognosis For CancersJHU REF: C12842Invention Novelty:This technology offers a prognostic panel derived from the gene expression of several different cancers, which was validated in multiple primary human samples. The panel, termed "AIM", differentiates patients into two tiers that correspond to a set of suggested treatment...

Published: 6/27/2024 | Inventor(s): Cynthia Zahnow, Stephen Baylin, Angela Guzzetta, Katherine Chiappinelli, Huili Li, Nita Ahuja

Keywords(s): Antagonists/Inhibitors, Biomarker, Cancers, Clinical Diagnostics, Combination, Disease Indication, Epithelial Cancer, In Vitro Diagnostics, Non-novel, Pharmakodynamic Biomarker, Predicted Novelty, Repurposed, Small Molecules, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology > Epithelial Cancer, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

Reprograming the Cancer Cells with Epigenetic Therapy (DNA Demethylating Agents and Histone Deacetylase Inhibitors) Sensitizes Multiple Cancers to PARP Inhibitors

Combinatorial Drug Therapy for CancersJHU REF: [C12345]Invention novelty: a combinatorial drug therapy for leukemia, ovarian, breast and lung cancers by targeting both epigenetic and DNA repair pathways.Value PropositionConventional forms of cancer drug therapy are limited in their results once the cancers exhibit resistance to existing drug regimens....

Published: 6/27/2024 | Inventor(s): Nidal Muvarak, Feyruz Rassool, Carine Robert, Stephen Baylin

Keywords(s): Antagonists/Inhibitors, Cancers, Combination, Disease Indication, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Targeted Therapy/Targeted Therapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Cancer Therapy via a Combination of Epigenetic Modulation and Immune Modulation

In addition to the conventional forms of cancer therapy (chemotherapy, surgery, radiation), newer forms of therapy, including epigenetic modulation with DNA demethylating agents and HDAC inhibitors and therapies targeted at the immune system, are being investigated. We have discovered that epigenetic modulation alters tumor gene expression so as to...

Published: 6/27/2024 | Inventor(s): Suzanne Topalian, Stephen Baylin, Drew Pardoll

Keywords(s): Antagonists/Inhibitors, Antibodies, Biologics, Biomarker, Cancers, Clinical Diagnostics, Combination, Disease Indication, Epigenetic, In Vitro Diagnostics, Non-novel, Predicted Novelty, Repurposed, Small Molecules, Targeted Therapy/Immunotherapy, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Small Molecules, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Therapeutic Modalities

C11897: N-Terminus FLAG tag on DNMT1

Technical Details: DNA methyldtransferase1 (DNMT1) is a maintenance methyltransferase enzyme; additional roles for DNMT1 in gene expression are not understood clearly. DNMT1 is shown to have repressive activity, and deletion of its catalytic domain does not abolish this activity. In this study Johns Hopkins researchers examine the repressor function...

Published: 6/27/2024 | Inventor(s): Stephen Baylin

Keywords(s): Basic Research Biomarker, Cloning Reagents, Discovery/Research Tools, Plasmid, Research Reagent

Category(s): Technology Classifications > Research Tools > Vectors & Plasmids, Technology Classifications > Research Tools

Cell Line Overexpressing DNA Methyltransferase

C09971: Cell Line Overexpressing DNA Methyltransferase Technical Details: Abnormal regional increases in DNA methylation, which have potential for causing gene inactivation and chromosomal instability, are consistently found in immortalized and tumorigenic cells. Increased DNA methyltransferase activity, which is also a characteristic of such cells,...

Published: 6/27/2024 | Inventor(s): Stephen Baylin

Keywords(s): Basic Research Biomarker, Cell Lines, Cloning Reagents, Discovery/Research Tools, In Vitro Research Tool, Methylation, Mouse Cell Lines, Research Reagent

Category(s): Technology Classifications > Research Tools > Animal Models, Technology Classifications > Research Tools > Cell Lines, Technology Classifications > Research Tools > Nucleic Acids, Technology Classifications > Research Tools

Hypermethylation of GATA-4 Transcription Factor Gene in Cancer

Methods are provided for identifying the presence of cancer cells in a sample by detecting hypermethylation of the promoter region of a GATA-4 transcription factor gene, a GATA-5 transcription factor gene, or both. Methods for ameliorating a cancer by effecting expression of a hypermethylation silenced GATA-4 and/or GATA-5 transcription also are pr...

Published: 6/27/2024 | Inventor(s): Yoshimitsu Akiyama, James Herman, Stephen Baylin

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics

A p105-based NF-(kappa) B Super repressor

C04290: A p105-based NF-(kappa) B Super repressor Technical Details: Nuclear factor (NF)-kB is a family of transcription factors that regulate immune and inflammatory responses, programmed cell death (apoptosis), and developmental processes. In normal cells, NF-kB is latent, and is activated transiently by stimuli and stresses. However, under pathological...

Published: 6/27/2024 | Inventor(s): Li Lin

Keywords(s): Biologics, Cancers, Chemotherapy, Disease Indication, Nucleic Acid, Single, Skin Cancer, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Dermatology, Clinical and Disease Specializations > Oncology > Skin Cancer, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities > Proteins, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities

Functional Identification of Methylated Cancer Genes

C04028: Functional Identification of Methylated Cancer GenesValue Proposition: • Molecular biomarkers frequently inactivated in primary tumors which displayed clear tumor suppressive activity • Rapid and robust method Technical Details: BACKGROUND Cancer of the esophagus is the eighth most common malignancy and ranks as the sixth most frequent...

Published: 6/27/2024 | Inventor(s): Hiromu Suzuki, Stephen Baylin, James Herman, David Sidransky

Keywords(s): Assay, Cancers, Clinical Diagnostics, Disease Indication, In Vitro Diagnostics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Diagnostics

1 2